Motif Bio Plc Total Liabilities 2015-2020 | MTFB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Motif Bio Plc total liabilities from 2015 to 2020. Total liabilities can be defined as the total value of all possible claims against the corporation.

Motif Bio Plc Total Liabilities 2015-2020 | MTFB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Motif Bio Plc total liabilities from 2015 to 2020. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.2B
Bristol Myers Squibb (BMY)	$121.3B
Gilead Sciences (GILD)	$120.8B
CSL (CSLLY)	$91.5B
Regeneron Pharmaceuticals (REGN)	$90.7B
GSK (GSK)	$75.3B
Alnylam Pharmaceuticals (ALNY)	$36.1B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$26.1B
Biogen (BIIB)	$25.1B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$16.5B
Incyte (INCY)	$15.7B
Genmab (GMAB)	$15.4B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.3B
Exelixis (EXEL)	$10.3B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10.1B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.8B
Ascendis Pharma (ASND)	$7.8B